We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01184014
First Posted: August 18, 2010
Last Update Posted: December 29, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
International Diabetes Center at Park Nicollet
Sanofi
Information provided by (Responsible Party):
HealthPartners Institute
  Purpose
The objective of this study is to determine the best insulin regimen for hospitalized patients who receive high doses of steroids who have high blood glucose.

Condition Intervention Phase
Hyperglycemia Drug: NPH insulin plus Complete Insulin Orders Drug: Complete Insulin Orders Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

Resource links provided by NLM:


Further study details as provided by HealthPartners Institute:

Primary Outcome Measures:
  • Mean Blood Glucose. [ Time Frame: discharge or until after their 5th day in the hospital ]
    as stated above


Secondary Outcome Measures:
  • the Mean Blood Glucose of All Blood Glucose Readings [ Time Frame: starting 3 hours after the initial index BG>180 measure, across the entire hospital stay or up through 5 days if hospital LOS is > 5 days ]
    as stated above


Enrollment: 72
Study Start Date: August 2010
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Experimental group
a study-specific steroid NPH dosing algorithm plus standard recommended care
Drug: NPH insulin plus Complete Insulin Orders
NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.
Other Names:
  • lantus
  • glargine
  • humalog
  • lispro
Active Comparator: Control group
the standard recommended care (Methodist Hospital Complete Insulin Orders)
Drug: Complete Insulin Orders
3-part insulin which includes background, meal-time and correction factor
Other Names:
  • lantus
  • glargine
  • humalog
  • lispro

Detailed Description:
The overall study objective of this research is to establish the efficacy and assure the safety of achieving glycemic control in hospitalized patients who receive greater than physiologic doses of steroids. This study will compare 2 methods of achieving glycemic control in hospitalized patients who develop steroid-induced hyperglycemia (blood glucose (BG) >180 mg/dL): 1) a study-specific steroid NPH dosing algorithm plus standard recommended care (Experimental group) vs. 2) the standard recommended care (Methodist Hospital Complete Insulin Orders (Control group).
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women aged ≥18 years who receive steroids in doses greater than physiologic replacement levels of ≥ 10 mg Prednisone or its equivalent of dexamethasone or methylprednisolone.
  • Have signed the consent form for the study
  • Have a BG > 180 mg/dL any time during the first 24 hour of steroid administration that is above physiological replacement ( ≥ 10 mg Prednisone or equivalent)
  • Are scheduled to be in hospital ≥ 2 days.

Exclusion Criteria:

  • Unable to read or understand English
  • History of psychiatric disability affecting informed consent or compliance with drug intake
  • Type 1 diabetes
  • Acute or chronic renal failure (creatinine clearance <30mL/min estimated by method of Cockcroft and Gault)
  • Patients in Hospice Care
  • Age <18 years
  • Previously enrolled in this study.
  • Not appropriate for the steroid protocol in judgment of the principal investigator and/or attending physician.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01184014


Locations
United States, Minnesota
Park Nicollet Health Services Methodist Hospital
St. Louis Park, Minnesota, United States, 55416
Sponsors and Collaborators
HealthPartners Institute
International Diabetes Center at Park Nicollet
Sanofi
Investigators
Principal Investigator: Richard M Bergenstal, MD International Diabetes Center at Park Nicollet
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: HealthPartners Institute
ClinicalTrials.gov Identifier: NCT01184014     History of Changes
Other Study ID Numbers: 04000-10-C
First Submitted: August 16, 2010
First Posted: August 18, 2010
Results First Submitted: September 13, 2013
Results First Posted: November 18, 2013
Last Update Posted: December 29, 2015
Last Verified: November 2013

Keywords provided by HealthPartners Institute:
corticosteroid
hyperglycemia
hospital
corticosteroid induced hyperglycemia in the hospital

Additional relevant MeSH terms:
Hyperglycemia
Glucose Metabolism Disorders
Metabolic Diseases
Insulin, Globin Zinc
Isophane insulin, beef
Insulin
Insulin Glargine
Insulin Lispro
Insulin, Isophane
Isophane Insulin, Human
Hypoglycemic Agents
Physiological Effects of Drugs